Fintel reports that on April 12, 2023, Barclays reiterated coverage of Haleon (LSE:HLN) with a Overweight recommendation.
Analyst Price Forecast Suggests 97.46% Downside
As of April 6, 2023, the average one-year price target for Haleon is $8.77. The forecasts range from a low of $6.40 to a high of $10.64. The average price target represents a decrease of 97.46% from its latest reported closing price of $345.75.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Haleon is $11,983MM, an increase of 10.36%. The projected annual non-GAAP EPS is $0.20.
What are Other Shareholders Doing?

TEQIX - Franklin Mutual Quest Fund holds 7,852K shares representing 0.09% ownership of the company.
JOHIX - JOHCM International Select Fund Institutional Shares holds 9,494K shares representing 0.10% ownership of the company. In it's prior filing, the firm reported owning 9,726K shares, representing a decrease of 2.44%. The firm increased its portfolio allocation in HLN by 37.91% over the last quarter.
Bokf, Na holds 27K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 28K shares, representing a decrease of 4.34%. The firm decreased its portfolio allocation in HLN by 99.90% over the last quarter.
Citizens Business Bank holds 10K shares representing 0.00% ownership of the company. No change in the last quarter.
QCGLRX - Global Equities Account Class R1 holds 1,122K shares representing 0.01% ownership of the company. In it's prior filing, the firm reported owning 1,142K shares, representing a decrease of 1.78%. The firm increased its portfolio allocation in HLN by 13.30% over the last quarter.
What is the Fund Sentiment?
There are 1040 funds or institutions reporting positions in Haleon. This is a decrease of 6 owner(s) or 0.57% in the last quarter. Average portfolio weight of all funds dedicated to HLN is 0.20%, an increase of 22.17%. Total shares owned by institutions increased in the last three months by 11.15% to 1,226,803K shares.
See all Haleon regulatory filings.This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.